About the Company

安立玺荣生物医药是一家处于临床阶段,全球布局的创新型生物医药技术公司。专注于创新型免疫治疗的新药研发,拥有*的自主研发平台,开发针对白癜风,阿尔兹海默, HLH,肿瘤等BIC/FIC(Best/First In Class)创新型免疫疗法。两次作为亚洲*企业荣膺微软创始人比尔盖兹(Bill Gates)与美国阿兹海默症协会(Alzheimers Association)合作的Part The Cloud-Gates Partnership学术科学奖项与”拨云计划“全球神经疾病研发项目奖励并已获得多家国际投资机构的青睐。公司已有两个产品进入临床研究阶段并获得IPF和HLH美国FDA的孤儿药认定,其中一个产品已进入II期临床开发。安立玺荣将持续进行全球前瞻性技术与创新应用的研发,不断巩固在创新性免疫疗法的核心竞争力。

Expand
Information is aggregated from the web and may not be exact. For reference only.
Information incorrect? Claim this company to edit

安立玺荣 Financing History (1 rounds)

Manage
B轮
Capital Market Favor
Latest Financing Round
  • Date: ?
  • Amount: 近亿人民币
  • Investor: 投资方未透露

安立玺荣 honors, qualifications & industry associations

Tags are labelled based on keyword text matching analysis and may be related to the company. For reference only.

安立玺荣 Related Industry Tags

Business Registration

Provided by

Operating Status: 开业
Registered Capital: 4,000万(元)
Legal Representative: 陈泓恺
Date Established:
Credit Code: 91310000MA1JB3TD5Y
Registered Address: 中国(上海)自由贸易试验区芳春路400号1幢3层

Report

*Reason:

Radical political or ideological topics
Advertising or spam
Pornographic or vulgar content
Obscene language or personal attacks
Other

Congratulations, submitted successfully!

Your edit is under review. You will be notified by email within 1 business day.

Submission failed.

Followed successfully. We'll notify you of any company updates.

Help others learn about this company, add my impression of this company»

Log in with the following accounts to save your follows

Followed successfully, we'll notify you of any company updates